Literature DB >> 14627400

Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.

Martin J Slater1, Elizabeth M Amphlett, David M Andrews, Paul Bamborough, Seb J Carey, Martin R Johnson, Paul S Jones, Gail Mills, Nigel R Parry, Donald O'N Somers, Alan J Stewart, Tadeusz Skarzynski.   

Abstract

[reaction: see text] In this, the first of two Letters, we describe how a P3/P4 urea linking unit was used to greatly enhance the biochemical and replicon potency of inhibitors based upon the pyrrolidine-5,5-trans-lactam template. Compound 7b demonstrated a 100 nM IC(50) in the replicon cell-based surrogate HCV assay.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627400     DOI: 10.1021/ol035826v

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  3 in total

1.  Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors.

Authors:  Victoria Chung; Anthony R Carroll; Norman M Gray; Nigel R Parry; Pia A Thommes; K Claire Viner; Eric A D'Souza
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus.

Authors:  Christoph Welsch; Francisco S Domingues; Simone Susser; Iris Antes; Christoph Hartmann; Gabriele Mayr; Andreas Schlicker; Christoph Sarrazin; Mario Albrecht; Stefan Zeuzem; Thomas Lengauer
Journal:  Genome Biol       Date:  2008-01-23       Impact factor: 13.583

3.  Systematic Studies on the Protocol and Criteria for Selecting a Covalent Docking Tool.

Authors:  Chang Wen; Xin Yan; Qiong Gu; Jiewen Du; Di Wu; Yutong Lu; Huihao Zhou; Jun Xu
Journal:  Molecules       Date:  2019-06-10       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.